+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 15Years +
All Genders
Healthy Volunteers
ID06807736

Study of Injectable, Oral, and Vaginal Ring HIV Prevention Choices for Adolescents and Young Adults in Cape Town

Led by Desmond Tutu HIV Foundation · Updated on 2025-02-04

1800

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to understand how adolescents and young people in Cape Town, South Africa use different HIV pre-exposure prophylaxis PrEP products over an 18-month period. It focuses on both clinical and practical aspects, such as how long participants continuously use PrEP without stopping or switching products, and what helps or hinders their decision to start and keep using PrEP. The study includes HIV-negative adolescent girls, young women, gender and sexually diverse youth aged 15-29, and their sexual partners of any age. Participants can choose from three PrEP options a daily oral tablet containing Tenofovir, a vaginal ring with Dapivirine that protects for up to one month, or an intramuscular injection of Cabotegravir lasting up to two months. They may stick with one product, switch between them, or pause and restart use at any time. The study takes place at two sites a mobile clinic that moves across the area and a fixed government healthcare clinic. Trained nurses provide PrEP and counseling designed with input from youth. Those who join will be followed for at least seven months to assess short-term use and up to 18 months for longer-term use. Researchers will collect information on product use, safety, tolerability, acceptability, and HIV testing practices. Participants choices and experiences with PrEP will be monitored through regular visits, with flexibility to access refills at either clinic. The study aims to provide insights into real-world PrEP use and factors influencing adherence and continuation.

CONDITIONS

Brief Title

PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here